Immunohistochemistry for an improved clinical workflow in the era of personalized melanoma therapy?

被引：0

作者：

Massi, Daniela ^{[1
]}

Mandala, Mario ^{[2
]}

机构：

[1] Univ Florence, Div Anat Pathol, Dept Surg Translat Med, Florence, Italy

[2] Papa Giovanni XXIII Hosp, Dept Hematol Oncol, Med Oncol Unit, Bergamo, Italy

来源：

MELANOMA MANAGEMENT | 2015年 / 2卷 / 01期

关键词：

BRAF; immunohistochemistry; mutation; NRAS;

D O I：

10.2217/MMT.14.27

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：5 / 8

页数：4

共 20 条

[1] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].

Ascierto, Paolo A. ;

Schadendorf, Dirk ;

Berking, Carola ;

Agarwala, Sanjiv S. ;

van Herpen, Carla M. L. ;

Queirolo, Paola ;

Blank, Christian U. ;

Hauschild, Axel ;

Beck, J. Thaddeus ;

St-Pierre, Annie ;

Niazi, Faiz ;

Wandel, Simon ;

Peters, Malte ;

Zubel, Angela ;

Dummer, Reinhard .

LANCET ONCOLOGY, 2013, 14 (03) :249-256

[2] Tumor Homogeneity between Primary and Metastatic Sites for BRAF Status in Metastatic Melanoma Determined by Immunohistochemical and Molecular Testing [J].

Boursault, Lucile ;

Haddad, Veronique ;

Vergier, Beatrice ;

Cappellen, David ;

Verdon, Severine ;

Bellocq, Jean-Pierre ;

Jouary, Thomas ;

Merlio, Jean-Philippe .

PLOS ONE, 2013, 8 (08)

[3] Immunohistochemical Analysis of BRAFV600E Expression of Primary and Metastatic Melanoma and Comparison With Mutation Status and Melanocyte Differentiation Antigens of Metastatic Lesions [J].

Busam, Klaus J. ;

Hedvat, Cyrus ;

Pulitzer, Melissa ;

von Deimling, Andreas ;

Jungbluth, Achim A. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2013, 37 (03) :413-420

[4] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[5] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[6] Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma [J].

Feller, John K. ;

Yang, Shi ;

Mahalingam, Meera .

MODERN PATHOLOGY, 2013, 26 (03) :414-420

[7] Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma [J].

Flaherty, Keith T. ;

Robert, Caroline ;

Hersey, Peter ;

Nathan, Paul ;

Garbe, Claus ;

Milhem, Mohammed ;

Demidov, Lev V. ;

Hassel, Jessica C. ;

Rutkowski, Piotr ;

Mohr, Peter ;

Dummer, Reinhard ;

Trefzer, Uwe ;

Larkin, James M. G. ;

Utikal, Jochen ;

Dreno, Brigitte ;

Nyakas, Marta ;

Middleton, Mark R. ;

Becker, Juergen C. ;

Casey, Michelle ;

Sherman, Laurie J. ;

Wu, Frank S. ;

Ouellet, Daniele ;

Martin, Anne-Marie ;

Patel, Kiran ;

Schadendorf, Dirk .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (02) :107-114

[8] Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial [J].

Hauschild, Axel ;

Grob, Jean-Jacques ;

Demidov, Lev V. ;

Jouary, Thomas ;

Gutzmer, Ralf ;

Millward, Michael ;

Rutkowski, Piotr ;

Blank, Christian U. ;

Miller, Wilson H., Jr. ;

Kaempgen, Eckhart ;

Martin-Algarra, Salvador ;

Karaszewska, Boguslawa ;

Mauch, Cornelia ;

Chiarion-Sileni, Vanna ;

Martin, Anne-Marie ;

Swann, Suzanne ;

Haney, Patricia ;

Mirakhur, Beloo ;

Guckert, Mary E. ;

Goodman, Vicki ;

Chapman, Paul B. .

LANCET, 2012, 380 (9839) :358-365

[9] NRAS mutation status is an independent prognostic factor in metastatic melanoma [J].

Jakob, John A. ;

Bassett, Roland L., Jr. ;

Ng, Chaan S. ;

Curry, Jonathan L. ;

Joseph, Richard W. ;

Alvarado, Gladys C. ;

Rohlfs, Michelle L. ;

Richard, Jessie ;

Gershenwald, Jeffrey E. ;

Kim, Kevin B. ;

Lazar, Alexander J. ;

Hwu, Patrick ;

Davies, Michael A. .

CANCER, 2012, 118 (16) :4014-4023

[10] The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition [J].

Jiang, Xiaofeng ;

Zhou, Jun ;

Giobbie-Hurder, Anita ;

Wargo, Jennifer ;

Hodi, F. Stephen .

CLINICAL CANCER RESEARCH, 2013, 19 (03) :598-609

← 1 2 →